Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NOTV |
---|---|---|
09:32 ET | 167 | 1.76 |
09:46 ET | 1400 | 1.71 |
09:48 ET | 300 | 1.72 |
10:02 ET | 1470 | 1.72 |
10:04 ET | 700 | 1.7299 |
10:06 ET | 100 | 1.73 |
10:08 ET | 100 | 1.7316 |
10:40 ET | 13940 | 1.78 |
10:45 ET | 200 | 1.8 |
10:49 ET | 2730 | 1.8299 |
10:56 ET | 2000 | 1.8 |
11:09 ET | 660 | 1.8 |
11:16 ET | 100 | 1.82 |
11:18 ET | 285 | 1.82 |
11:21 ET | 1327 | 1.82 |
11:23 ET | 1025 | 1.81 |
11:25 ET | 1100 | 1.81 |
11:32 ET | 4999 | 1.82 |
11:36 ET | 200 | 1.8208 |
11:38 ET | 759 | 1.8208 |
11:43 ET | 5454 | 1.82 |
11:54 ET | 200 | 1.78 |
11:59 ET | 1501 | 1.79 |
12:06 ET | 720 | 1.79 |
12:24 ET | 100 | 1.8 |
12:30 ET | 100 | 1.8 |
12:37 ET | 6475 | 1.73 |
12:51 ET | 1500 | 1.74 |
12:57 ET | 805 | 1.75 |
01:04 ET | 425 | 1.76 |
01:13 ET | 13629 | 1.75 |
01:15 ET | 882 | 1.752 |
01:40 ET | 2602 | 1.75 |
01:42 ET | 100 | 1.755 |
01:44 ET | 3718 | 1.7689 |
01:56 ET | 3346 | 1.765 |
02:02 ET | 100 | 1.74 |
02:21 ET | 2541 | 1.77 |
02:38 ET | 100 | 1.77 |
02:52 ET | 683 | 1.77 |
03:03 ET | 2205 | 1.77 |
03:12 ET | 5122 | 1.755 |
03:17 ET | 10470 | 1.76 |
03:24 ET | 100 | 1.75 |
03:33 ET | 100 | 1.76 |
03:35 ET | 5200 | 1.75 |
03:42 ET | 200 | 1.75 |
03:44 ET | 1100 | 1.7598 |
03:50 ET | 600 | 1.76 |
03:53 ET | 1790 | 1.7701 |
04:00 ET | 2942 | 1.75 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Inotiv Inc | 46.3M | -0.5x | --- |
Organogenesis Holdings Inc | 368.6M | -23.9x | --- |
Sinovac Biotech Ltd | 639.9M | -4.9x | --- |
Ironwood Pharmaceuticals Inc | 669.3M | 97.0x | --- |
Amylyx Pharmaceuticals Inc | 384.0M | -2.3x | --- |
Amarin Corporation PLC | 240.9M | -6.3x | --- |
Inotiv, Inc. is a contract research company, which is engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. The RMS segment offer access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $46.3M |
---|---|
Revenue (TTM) | $501.1M |
Shares Outstanding | 26.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 3.40 |
EPS | $-3.84 |
Book Value | $10.44 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 0.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -14.13% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.